Trevi Therapeutics (TRVI) Short Interest Ratio & Short Volume → 2024's Must-Have Guide: Master Crypto Investment Today (From Darwin) (Ad) Free TRVI Stock Alerts $2.71 +0.02 (+0.74%) (As of 03:10 PM ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Trevi Therapeutics Short Interest DataCurrent Short Volume1,040,000 sharesPrevious Short Volume1,070,000 sharesChange Vs. Previous Month-2.80%Dollar Volume Sold Short$3.59 millionShort Interest Ratio / Days to Cover3.5Last Record DateMarch 31, 2024Outstanding Shares68,960,000 sharesPercentage of Shares Shorted1.51%Today's Trading Volume75,664 sharesAverage Trading Volume280,443 sharesToday's Volume Vs. Average27% Short Selling Trevi Therapeutics ? Sign up to receive the latest short interest report for Trevi Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatTRVI Short Interest Over TimeTRVI Days to Cover Over TimeTRVI Percentage of Float Shorted Over Time Ad Tips4TradersUncover this 2024 Hidden GemExclusive Report: Uncover a Hidden Investment Gem We’re excited to share a special report on one exceptional, publicly traded company. This company has achieved a remarkable 22+% just this year, outperforming the market and revealing the potential for significant gains.[Click here to subscribe] and elevate your trading today. Trevi Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 3/31/20241,040,000 shares $3.59 million -2.8%N/A3.5 $3.45 3/15/20241,070,000 shares $3.58 million -13.7%N/A3.8 $3.35 2/29/20241,240,000 shares $3.62 million +4.2%N/A4.2 $2.92 2/15/20241,190,000 shares $2.83 million -13.8%N/A2.7 $2.38 1/31/20241,380,000 shares $1.96 million +11.3%N/A3.6 $1.42 1/15/20241,240,000 shares $1.76 million +6.0%N/A3.2 $1.42 Get the Latest News and Ratings for TRVI and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Trevi Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 12/31/20231,170,000 shares $1.57 million +15.8%N/A3.1 $1.34 12/15/20231,010,000 shares $1.29 million -7.3%N/A2.8 $1.28 11/30/20231,090,000 shares $1.23 million -4.4%N/A3.4 $1.13 11/15/20231,140,000 shares $1.57 million -1.7%N/A6.4 $1.38 10/31/20231,160,000 shares $2.06 million -4.9%N/A14 $1.78 10/15/20231,220,000 shares $2.48 million -3.2%N/A18.8 $2.03 9/30/20231,260,000 shares $2.75 million -4.6%N/A17.5 $2.18 9/15/20231,320,000 shares $3.10 million +0.8%N/A14.1 $2.35 8/31/20231,310,000 shares $2.90 million -3.7%N/A6.5 $2.21 8/15/20231,360,000 shares $3.29 million +3.0%N/A4.1 $2.42 7/31/20231,320,000 shares $3.14 million +1.5%N/A3.6 $2.38 7/15/20231,300,000 shares $2.81 million -2.3%N/A3.3 $2.16 6/30/20231,330,000 shares $3.18 million +482.8%N/A3.5 $2.39 6/15/2023228,200 shares $588,756.00 -5.9%N/A0.6 $2.58 5/31/2023242,600 shares $524,016.00 -2.1%N/A1 $2.16 5/15/2023247,900 shares $654,456.00 -11.6%N/A1.5 $2.64 4/30/2023280,300 shares $964,232.00 +39.2%N/A3.4 $3.44 4/15/2023201,300 shares $380,457.00 +15.4%N/A3.2 $1.89 3/31/2023174,400 shares $322,640.00 +51.9%N/A3.6 $1.85 3/15/2023114,800 shares $210,084.00 +73.2%N/A1.1 $1.83 2/28/202366,300 shares $158,457.00 -15.8%N/A0.6 $2.39 2/15/202378,700 shares $201,472.00 -11.6%N/A0.7 $2.56 1/31/202389,000 shares $207,370.00 -7.0%N/A0.8 $2.33 1/15/202395,700 shares $250,734.00 +0.8%N/A0.8 $2.62 12/30/202294,900 shares $183,157.00 -40.6%N/A0.7 $1.93 12/15/2022159,800 shares $356,354.00 -34.2%N/A0.8 $2.23 11/30/2022242,800 shares $456,464.00 -16.3%N/A1.2 $1.88 11/15/2022289,900 shares $637,780.00 -1.9%N/A1.2 $2.20 10/31/2022295,600 shares $585,288.00 -27.0%N/A1.1 $1.98 10/15/2022405,100 shares $725,129.00 +264.0%N/A1.3 $1.79 9/30/2022111,300 shares $171,402.00 +12.5%N/A0.3 $1.54 9/15/202298,900 shares $306,590.00 -9.9%N/A0.1 $3.10 8/31/2022109,700 shares $348,846.00 -2.3%0.6%0.1 $3.18 8/15/2022112,300 shares $424,494.00 -19.1%0.6%0.1 $3.78Uncover this 2024 Hidden Gem (Ad)Exclusive Report: Uncover a Hidden Investment Gem We’re excited to share a special report on one exceptional, publicly traded company. This company has achieved a remarkable 22+% just this year, outperforming the market and revealing the potential for significant gains.[Click here to subscribe] and elevate your trading today. TRVI Short Interest - Frequently Asked Questions What is Trevi Therapeutics' current short interest? Short interest is the volume of Trevi Therapeutics shares that have been sold short but have not yet been closed out or covered. As of March 31st, investors have sold 1,040,000 shares of TRVI short. Learn More on Trevi Therapeutics' current short interest. What is a good short interest ratio for Trevi Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. TRVI shares currently have a short interest ratio of 4.0. Learn More on Trevi Therapeutics's short interest ratio. Which institutional investors are shorting Trevi Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Trevi Therapeutics: Citadel Advisors LLC, and Concourse Financial Group Securities Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. Is Trevi Therapeutics' short interest increasing or decreasing? Trevi Therapeutics saw a decline in short interest during the month of March. As of March 31st, there was short interest totaling 1,040,000 shares, a decline of 2.8% from the previous total of 1,070,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Trevi Therapeutics' short interest compare to its competitors? Here is how the short interest of companies in the sector of "medical" compare to Trevi Therapeutics: Veru Inc. (6.77%), Gossamer Bio, Inc. (4.77%), Greenwich LifeSciences, Inc. (2.41%), Capricor Therapeutics Inc (11.11%), Alimera Sciences, Inc. (0.21%), Adicet Bio, Inc. (9.36%), 23andMe Holding Co. (11.72%), Inventiva S.A. (0.11%), Atossa Therapeutics, Inc. (8.43%), Organigram Holdings Inc. (5.43%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: TC Energy Co. ($4.49 billion), T-Mobile US, Inc. ($3.94 billion), General Motors ($3.34 billion), Charter Communications, Inc. ($3.32 billion), Occidental Petroleum Co. ($3.21 billion), Super Micro Computer, Inc. ($3.13 billion), Coinbase Global, Inc. ($3.08 billion), Moderna, Inc. ($2.28 billion), Tractor Supply ($2.24 billion), and Royal Caribbean Cruises Ltd. ($2.14 billion). View all of the most shorted stocks. What does it mean to sell short Trevi Therapeutics stock? Short selling TRVI is an investing strategy that aims to generate trading profit from Trevi Therapeutics as its price is falling. TRVI shares are trading up $0.04 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Trevi Therapeutics? A short squeeze for Trevi Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of TRVI, which in turn drives the price of the stock up even further. How often is Trevi Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including TRVI, twice per month. The most recent reporting period available is March, 31 2024. More Short Interest Resources from MarketBeat Related Companies: VERU Short Interest Data GOSS Short Interest Data GLSI Short Interest Data CAPR Short Interest Data ALIM Short Interest Data ACET Short Interest Data ME Short Interest Data IVA Short Interest Data ATOS Short Interest Data OGI Short Interest Data Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:TRVI) was last updated on 4/19/2024 by MarketBeat.com Staff From Our PartnersThe “Perfect Storm” for GoldGold Safe ExchangeThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingBiden’s $374B Giveaway Into This SectorDTIHe Is Giving Away BitcoinCrypto Swap ProfitsYour Money is Not SafeAmerican AlternativeThe #1 Crypto for 2024InvestorPlaceSHOCKING Crypto Leak…Crypto 101 MediaMy biggest AI fearParadigm Press